Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 15/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 7/20 | 0.48 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13845900 | 1.00 | PSMB5 (0.50) | PSMB5PSMB8MEP1BMRGPRX4TP53 | |
| SCHEMBL3655369 | 0.88 | PSMB5 (0.61) | PSMB5PSMB8MRGPRX4TP53PKM | |
| SCHEMBL13845967 | 0.88 | PSMB5 (0.61) | PSMB5PSMB8MRGPRX4TP53PKM | |
| SCHEMBL13845899 | 0.86 | PSMB5 (0.61) | PSMB5PSMB8MEP1BMRGPRX4TP53 | |
| SCHEMBL3653865 | 0.86 | PSMB5 (0.60) | PSMB5PSMB8MEP1BMRGPRX4TP53 | |
| SCHEMBL13845895 | 0.86 | PSMB5 (0.56) | PSMB5PSMB8 | |
| SCHEMBL3662229 | 0.86 | PSMB5 (0.61) | PSMB5PSMB8MEP1BMRGPRX4TP53 | |
| SCHEMBL13846026 | 0.86 | PSMB5 (0.60) | PSMB5PSMB8MEP1BMRGPRX4TP53 | |
| SCHEMBL3660195 | 0.86 | PSMB5 (0.56) | PSMB5PSMB8 | |
| SCHEMBL13846042 | 0.81 | PSMB5 (0.68) | PSMB5PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| EP-2220096-A1 | BETA-LACTAMASE INHIBITORS | Protez Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009064413-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PSMB5 1165/4885PSMB8 1092/4885MEP1B 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.